Old Web
English
Sign In
Acemap
>
authorDetail
>
Andreas Port
Andreas Port
Merck KGaA
Pharmacology
Medicine
Pharmacokinetics
Placebo
Antagonist
2
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants.
2021
Clinical and Translational Science
Holger Scheible
Martin Dyroff
Annick Seithel-Keuth
Eleanor Harrison-Moench
Nadra Mammasse
Andreas Port
Angelika Bachmann
Jennifer Dong
Jan J. van Lier
William Tracewell
David Mitchell
Show All
Source
Cite
Save
Citations (0)
Phase 1 study in healthy participants of the safety, pharmacokinetics, and pharmacodynamics of enpatoran (M5049), a dual antagonist of toll-like receptors 7 and 8.
2021
Pharmacology Research & Perspectives
Andreas Port
Jamie V. Shaw
Lena Klopp‐Schulze
Afrim Bytyqi
Claudia Vetter
Elizabeth Hussey
Nadra Mammasse
Victor Ona
Angelika Bachmann
Denis Strugala
Christian Reh
Kosalaram Goteti
Show All
Source
Cite
Save
Citations (0)
1